×
About 15,003 results

ALLMedicine™ Atopic Dermatitis Center

Research & Reviews  4,699 results

Interleukins 4 and 13 drive lipid abnormalities in skin cells through regulation of sex...
https://doi.org/10.1073/pnas.2100749118
Proceedings of the National Academy of Sciences of the Un... Zhang C, Chinnappan M et. al.

Sep 16th, 2021 - Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by skin dryness, inflammation, and itch. A major hallmark of AD is an elevation of the immune cytokines IL-4 and IL-13. These cytokines lead to skin barrier disruption and...

A qualitative and quantitative comparison of IgE antibody profiles with two multiplex p...
https://doi.org/10.1111/cea.14016
Clinical and Experimental Allergy : Journal of the Britis... Scala E, Caprini E et. al.

Sep 16th, 2021 - Clinically complex phenotypes require more and more sophisticated and comprehensive diagnostic approaches, able to discriminate genuine sensitizations from cross-reactivity. Interpretative complexity of multiplex diagnostic arrays has somewhat lim...

Experience using dupilumab for pediatric atopic dermatitis at a tertiary care c enter: ...
https://doi.org/10.1111/pde.14799
Pediatric Dermatology; McKenzie PL, Rangu S et. al.

Sep 14th, 2021 - Dupilumab is highly effective in treating atopic dermatitis (AD). However, some patients experience difficulties with dupilumab therapy, such as inadequate clinical response, failure to achieve long-term disease control, or adverse events (AEs). O...

Impact and Associations of Atopic Dermatitis Out-of-Pocket Health Care Expenses in the ...
https://doi.org/10.1097/DER.0000000000000795
Dermatitis : Contact, Atopic, Occupational, Drug; Chovatiya R, Begolka WS et. al.

Sep 14th, 2021 - Atopic dermatitis (AD) is associated with substantial financial cost, including increased out-of-pocket (OOP) expenses. Associations and impact of OOP cost are poorly understood. The aim of the study was to characterize the impact and associations...

see more →

Guidelines  8 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Considerations on biologicals for patients with allergic disease in times of the COVID-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300800
Allergy Vultaggio A, Agache I et. al.

Jun 6th, 2020 - The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex pat...

European task force on atopic dermatitis position paper: treatment of parental atopic d...
https://doi.org/10.1111/jdv.15709
Journal of the European Academy of Dermatology and Venere... Vestergaard C, Wollenberg A et. al.

Jun 25th, 2019 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the trea...

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) ...
https://doi.org/10.1111/jdv.14891
Journal of the European Academy of Dermatology and Venere... Wollenberg A, Barbarot S et. al.

Apr 21st, 2018 - This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic revi...

The microbiome in allergic disease: Current understanding and future opportunities-2017...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899886
The Journal of Allergy and Clinical Immunology; Huang YJ, Marsland BJ et. al.

Mar 5th, 2017 - PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and ...

see more →

Drugs  430 results see all →

Clinicaltrials.gov  21 results

Open-label Maximum Use Trial of Ruxolitinib Cream in Children With Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT05034822

Sep 5th, 2021 - Open-label, BID application to all affected areas identified at BSLN for 4 weeks (maximum use trial (MUsT) period). The next 4 weeks (treatment extension period) will be applied BID to active lesions only for the next 4 weeks for a total treatment...

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
https://clinicaltrials.gov/ct2/show/NCT04392154

Sep 5th, 2021 - Participants who have completed participation in a Dermira- or Lilly-sponsored lebrikizumab study (parent study), DRM06-AD04, DRM06-AD05, DRM06-AD06, DRM06-AD17 or DRM06- AD18, will be offered the opportunity to enroll in this study. Participants ...

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
https://clinicaltrials.gov/ct2/show/NCT05032859

Sep 2nd, 2021 - This study is a 8-week double-blind, vehicle-controlled treatment study in which subjects will be randomized to receive tapinarof cream, 1% or vehicle cream once daily for 8 weeks. At the end of the 8-week study treatment, qualified subjects will ...

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
https://clinicaltrials.gov/ct2/show/NCT04345367

Aug 31st, 2021 - This is a randomized, double-blind, double-dummy, active-controlled, multi-center study to assess the efficacy and safety of abrocitinib 200 mg (2 x 100 mg tablets) administered orally QD compared with dupilumab 300 mg administered by subcutaneous...

Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients
https://clinicaltrials.gov/ct2/show/NCT05019209

Aug 30th, 2021 - Atopic dermatitis (AD) is a chronic skin disease characterized by a relapsing course and typical clinical manifestation with itchy, eczematous lesions. The majority of AD patients reveals elevated IgE serum levels (> 100kU / L), which classifies t...

see more →

News  841 results

Proposed Classification Framework for Atopic Dermatitis Unveiled
https://www.medscape.com/viewarticle/954902

Jul 16th, 2021 - The heterogeneous clinical course of atopic dermatitis (AD) and its differing signs, symptoms, burden, and response to treatment can pose a quandary for physicians. Dr Jonathan Silverberg This is behind a new classification framework called DESCRI...

Dupilumab Safe, Effective in Kids 6-11 With Moderate-to-Severe Asthma
https://www.medscape.com/viewarticle/954586

Jul 10th, 2021 - Dupilumab (Dupixent, Sanofi and Regeneron) significantly reduced exacerbations compared with placebo in children ages 6-11 years who had moderate-to-severe asthma in a phase 3 trial. A fully human monoclonal antibody, dupilumab also improved lung ...

Study Provides Insights Into Pediatric Psoriasis Over Two Decades
https://www.medscape.com/viewarticle/954411

Jul 8th, 2021 - Obesity, atopic dermatitis, psychiatric disease, and arthritis are the most common comorbidities among infants, children, and adolescents with psoriasis, while predictors of moderate to severe disease include morphology, non-White race, and cultur...

Expert Shares Practical Considerations for Dupilumab Treatment
https://www.medscape.com/viewarticle/954120

Jul 1st, 2021 - Clinicians who struggle to get dupilumab approved for their patients with moderate to severe atopic dermatitis (AD) are not alone. This scenario was illustrated in a 2020 retrospective study of 179 adults with AD who were cared for at the Universi...

Baricitinib Found Effective for Moderate to Severe AD Out to 52 Weeks
https://www.medscape.com/viewarticle/953944

Jun 29th, 2021 - Baricitinib, at a dose of 2 mg a day, demonstrated efficacy in adults with moderate to severe atopic dermatitis up to 52 weeks, integrated data from two trials demonstrated. "With long-term therapy, the baricitinib 2 mg response remains stable or ...

see more →

Patient Education  2 results see all →